Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Major Depressive Disorder
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Triple (Participant, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 50 years
- Gender
- Both males and females
Description
This is a 16-week, placebo-controlled, randomized, double-blind, clinical trial, involving 60 obese individuals with MDD and pre-treatment cognitive dysfunction. Study participants will receive one of the following study interventions in addition to 'standard of care' treatment: once-daily semagluti...
This is a 16-week, placebo-controlled, randomized, double-blind, clinical trial, involving 60 obese individuals with MDD and pre-treatment cognitive dysfunction. Study participants will receive one of the following study interventions in addition to 'standard of care' treatment: once-daily semaglutide, initiated at 3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks; or matching placebo. Participants will be assessed to examine the effect of semaglutide on their cognitive function.
Tracking Information
- NCT #
- NCT04466345
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Rodrigo B. Mansur, MD, PhD University Health Network, Toronto
Get Well Soon